BioCentury | Jun 13, 2016
Clinical News

CaCP29: Phase II started

InflaRx began the double-blind, placebo-controlled, German Phase II CARDIAC trial to evaluate IFX-1 in 100 patients undergoing complex cardiac surgery. The surgery is defined as invasive open heart and/or aortic trunk surgical procedures requiring cardiopulmonary...
BioCentury | Aug 11, 2011
Distillery Therapeutics

Indication: Autoimmune disease

...human studies suggest the enzyme CPB2 could help treat RA. In mouse models of RA, Cpb2...
...half-life, and increased C5a cleavage compared with the wild-type CPB2. Ongoing work includes testing exogenous CPB2...
BioCentury | Apr 5, 2010
Clinical News

Ecallantide: Development discontinued

Cubist discontinued development of ecallantide after reviewing top-line data from the CONSERV-1 and CONSERV-2 Phase II trials. In the double-blind, U.S. CONSERV-1 trial in 249 patients undergoing coronary artery bypass graft (CABG) surgery while on...
BioCentury | Apr 1, 2010
Clinical News

Cubist discontinues ecallantide

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) discontinued development of ecallantide ( CB-500,929 ) after reviewing top-line data from the double-blind CONSERV-1 and CONSERV-2 Phase II trials to reduce blood loss during on-pump cardiac surgery. In CONSERV-1, IV ecallantide showed...
BioCentury | Aug 24, 2009
Finance

Ebb & Flow

Having granted U.S. marketing rights to Intermezzo zolpidem to Purdue Pharma L.P. earlier this month, Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) last week said it would cut the staff made superfluous by the deal. It will trim...
BioCentury | Apr 28, 2008
Clinical News

Veletri tezosentan: Development discontinued

Actelion discontinued development of Veletri tezosentan, which was in Phase III testing, after "the observed event rate and effect in a recently concluded study in cardiac bypass separation was lower than expected and would have...
BioCentury | Apr 28, 2008
Finance

EPS watch

EPS watch Company 1Q08 EPS est 1Q08 EPS actual Outcome Growth from 1Q07 4/25 cls Wk chg % chg Mcap chg 4/25 Mcap Actelion (SWX:ATLN) NA CHF0.63 NA -28% CHF53.80 CHF4.3 9% $526.2 $6,584.2 Actelion...
BioCentury | Apr 23, 2008
Company News

Actelion drops tezosentan, reports earnings

In its 1Q08 earnings, Actelion (SWX:ATLN) disclosed that it discontinued development of tezosentan. The company said the decision was made because "the observed event rate and effect in a recently concluded study in cardiac bypass...
BioCentury | Oct 20, 2007
Politics & Policy

Aetna issues new ESA policy

Private insurer Aetna issued a new policy regarding its coverage of erythropoiesis-stimulating agents (ESAs) that is less restrictive than that of the Centers for Medicare & Medicaid Services (CMS). For example, Aetna would cover ESA...
BioCentury | Jul 30, 2007
Clinical News

Veletri tezosentan: Phase III started

ATLN said last half it began a double-blind, placebo-controlled, international Phase III trial. Actelion Ltd. (SWX:ATLN), Allschwil, Switzerland Product: Veletri tezosentan Business: Cardiovascular Molecular target: Endothelin A receptor ; Endothelin B receptor Description: Endothelin receptor...
Items per page:
1 - 10 of 72